Open access peer-reviewed chapter

Pituitary Apoplexy

Written By

Manel Jemel, Wafa Alaya, Fedia Boubaker, Olfa Berrich and Baha Zantour

Submitted: February 6th, 2018 Reviewed: April 16th, 2018 Published: November 5th, 2018

DOI: 10.5772/intechopen.77270

From the Edited Volume

Pituitary Diseases

Edited by Fawaz Assaad, Hansdetlef Wassmann and Maher Khodor

Chapter metrics overview

1,352 Chapter Downloads

View Full Metrics

Abstract

Pituitary apoplexy is a rare clinical emergency due to acute ischemic infarction or hemorrhage of the pituitary gland. As this disorder most often involves a pituitary adenoma, especially nonfunctioning tumors, the syndrome should be referred to as pituitary tumor apoplexy. The precise physiopathology is not completely clear. Although in most cases it occurs spontaneously, pituitary apoplexy can be precipitated by many risk factors. The main symptom is headache of sudden onset associated with visual disturbances, signs of meningeal irritation, and/or endocrine dysfunction. Corticotropic deficiency is a potentially life-threatening disorder. Magnetic resonance imaging is the most sensitive to confirm the diagnosis by revealing a pituitary tumor with hemorrhagic and/or necrotic components. Earlier studies used to consider urgent decompression of the lesion surgically, but nowadays, more recent studies favor conservative management in selected patients (those without important visual acuity or field defects and with normal consciousness). This wait-and-see approach gives evidence of excellent outcomes in terms of oculomotor palsy, pituitary function, and subsequent tumor growth. Surgical decompression may be necessary in some cases. Once the acute phase is over, the patient should be reevaluated for hormonal deficiencies. Moreover, spontaneous remission of syndromes, such as acromegaly, may be caused by pituitary adenoma apoplexy.

Keywords

  • apoplexy
  • hypopituitarism
  • pituitary adenoma
  • pituitary MRI

1. Introduction

The term “pituitary apoplexy” (PA) originating from Greek means “sudden attack” with hemorrhage and/or infarction in the pituitary tumor or, less commonly, the surrounding normal gland tissue.

The first index case was, described by Bailey, in 1898 [1], but the term pituitary apoplexy was coined by Broughamin in 1950 [2].

Pituitary tumor apoplexy is an uncommon acute clinical syndrome and one of the rare problems that is diagnostically and therapeutically challenging.

PA is frequently the onset of unknown preexisting pituitary adenoma. The clinical spectrum of presentation does vary but often reserved only for classical presentation in contrast to “Silent, subclinical or asymptomatic pituitary tumor apoplexy” even though the latter is the more frequent entity [3].

It is a potentially life-threatening complication requiring a rapid diagnosis and appropriate treatment.

The diagnosis of pituitary tumor apoplexy is based on imaging evaluations, mainly using magnetic resonance imaging.

The best approach in the acute phase is still controversial, and nowadays, PA is no longer considered as a neurosurgical emergency [4, 5].

The outcome of acute apoplexy is variable and remains difficult to predict; a regular input and follow-up from a multidisciplinary team including neurosurgeons, endocrinologists, neuro-ophthalmologists, neuroradiologists, and neurologists are mandatory.

Advertisement

2. Epidemiological data

Pituitary tumor apoplexy appears to be rare. The true incidence and prevalence of PA are difficult to establish either because the majority of the studies are retrospectives or because the diagnosis of PA is usually misdiagnosed and simply identified at surgery or during radiological investigation or pathological examination. According to the main retrospective series, an estimated prevalence of 6.2 cases per 100,000 inhabitants and [6] an incidence of 0.17 episodes per 100,000 person-years were reported [7].

In published series of surgically resected pituitary adenomas, PA can occur in 0.6–10% with a mean of 2% of all adenomas and has reached 21% in an unusual report [8]. Nonfunctioning pituitary adenomas (NFPA) appear to be at higher risk of apoplexy with an incidence of 0.2–0.6 events per 100 person-years [9]. In published series of nonfunctioning pituitary adenomas, the frequency of apoplexy can vary from 3.7 to 21% [10]. Nonsecreting pituitary adenomas represent an average of 45–70% of adenomas with apoplexy [3].

Apoplexy represents the first clinical manifestation of previously unknown pituitary adenoma in 60–80% of cases [5, 11, 12].

Pituitary tumor apoplexy can occur at all ages, but most cases are seen during the fifth or sixth decade of life. In adolescents, this event has been described by Jankoswski and cols as a very rare entity [13].

There is a discrete preponderance in males ranging from 1.1 to 2.3/1 [5, 12].

Macroadenomas, especially nonfunctioning, and prolactinomas are most susceptible to apoplexy; nevertheless, apoplexy in other tumor types such as GH-secreting or clinically silent ACTH adenomas has been reported [5].

Microadenomas may also be prone to apoplexy [14]. PA occurs in 0.6–10% of treated pituitary adenomas. In three series of macroprolactinomas, the ratio of apoplexy/therapy varied between 1.2 and 6.67% [14].

In a review, apoplexy was found to occur in 1–6% of macroprolactinomas. This average was comparable between treated and untreated adenomas [5].

Semple et al. have found that one-third of their 62 patients had only infarction [15]. Hemorrhage is more associated with macroprolactinoma and female gender [16].

Advertisement

3. Pathophysiology

The pathophysiological mechanisms of pituitary tumor apoplexy remain incompletely understood. There are various theories upon the pathophysiology of pituitary apoplexy in the current literature. It is uncertain whether the pathological process is a primary hemorrhage or whether the event is really a hemorrhagic infarction. Many pathogenic mechanisms have been proposed. Given that the risk of hemorrhage in a pituitary adenoma appears to be five times higher than in other intracranial neoplasms, intrinsic factors can be involved in the apoplectic event [12]. The rich and the complex vascular system makes the pituitary adenomas more vulnerable to bleed than any other brain tumor.

Understanding the vascularity of the pituitary gland and pituitary adenomas is crucial for etiopathogenesis of apoplexy.

As shown by the angiographic studies, the adenomas are mostly supplied by inferior pituitary artery, and its arterial flux is reduced compared with the normal pituitary [17].

The number and size of vessels are generally lesser than the normal pituitary vessels and are divided into irregular islets. Under electronic microscopy, they have incomplete maturation, poor fenestration, and ruptured and fragmented basal membranes with perivascular spaces filled with plasmatic proteins or red cells that may predispose to hemorrhage [18].

The fragility of the constitutional tumoral vascularization, can be explained by an increased expression of vascular endothelial growth factor “VEGF mRNA” in pituitary tumors; especially in nonfunctioning pituitary adenomas [14].

This expression of vascular endothelial growth factor could be explained by a tumoral overexpression of the pituitary tumor transforming and was found to correlate positively with the risk of pituitary hemorrhage. Other vascular markers were reported such as fetal liver kinase 1, nestin, etc. [5].

All the conditions associated with an acute increase in blood flow or coagulation disturbs may predispose these lesions to hemorrhage or hemorrhagic infarction [14].

This intratumoural vasculopathy, limited blood supply of the pituitary adenomas, and limited expression of angiogenic factors contrast with a high-energy requirement. As consequence, any extrinsic factor that alters the balance between tumor perfusion and tumor metabolism may cause an acute ischemia or infarction [17].

Moreover, an increased intratumoural and intrasellar pressure could concur to the reduction of tumor perfusion, further contributing to ischemia’s pathomechanisms. Tumor growth could thus contribute to ischemia which explains the size of the adenoma being a major factor. Macroadenomas are described to be at a much higher risk of apoplexy than microadenomas [10, 19, 20].

Germline AIP gene mutations may be associated with a rapid growth of the pituitary adenomas predisposing them to apoplexy [21].

Advertisement

4. Predisposing factors

PA can occur without any risk factors; however, numerous conditions have been linked to PA. Precipitating factors are identified in 10–40% of cases [3] (Table 1).

Table 1.

Precipitating factors of pituitary apoplexy.

4.1. Precipitating factors

The multiple factors reported as precipitating PA can be classified into three categories.

4.1.1. Acute variations of the blood flow in the pituitary gland

Procedures such as angiography, pneumoencephalography, myelography, lumbar puncture, and spinal anesthesia have been associated with PA. Blood pressure (BP) fluctuations or vasospasm may explain PA [22, 23]. Pituitary irradiation may induce vascular changes leading to chronic hypoperfusion of the pituitary gland and has been associated with both pituitary infarction and pituitary hemorrhage [24, 25]. Closed-head trauma which often minor may be a cause of PA, explained by acute changes in the intracranial pressure and in blood pressure [26].

PA has been described in postoperative states. Orthopedic and cardiac surgeries mainly cardiopulmonary bypass were the most incriminated [27, 28, 29]. Intra- or postoperative hypotension, anticoagulation, and microemboli leading to infarction were the proposed mechanisms. If a pituitary adenoma is known before the cardiac procedure, some authors recommend the use of off-pump technique maintaining an adequate systemic perfusion, as opposed to standard cardiopulmonary bypass [30].

Systemic hypertension leading to an increase in blood flow and diabetes mellitus has been associated with PA [31, 32]. However, this association was not confirmed by other studies [10, 33].

Severe vomiting/diarrhea with concomitant increased Valsalva pressure may also decrease blood supply to the pituitary adenoma and precipitate apoplexy, since tumoral cells are particularly sensitive to glucose deprivation [5].

4.1.2. Imbalance between the stimulation of the pituitary and the ability of increased blood flow at the level of the pituitary adenoma

Apoplexy can also occur after dynamic testing of the pituitary (insulin, TRH, GnRH, or GHRH tests and much more rarely CRH) particularly when different agents are combined. Numerous publications have documented the occurrence of apoplexy within minutes to hours after testing [10, 34, 35].

In this setting, TRH dynamic test may cause apoplexy by vasospasm induced by increased norepinephrine levels or by elevating systemic pressure.

Other tests of pituitary stimulation (especially use of GnRH) can increase the imbalance between the intratumoral metabolic demand and the poor tumor perfusion.

Reports of PA occurring after stimulation test are much rarer in the recent past. Currently, pituitary dynamic testing is not commonly used in the routine assessment of hypothalamic pituitary function.

Increased estrogen states, such as exogenous estrogen administration, pregnancy, and postpartum period, have been reported to cause PA [33, 36, 37, 38]. Treatment with GnRH agonists for prostate cancer has also been associated with PA [39, 40, 41].

The role of dopamine agonist (DAs) treatment as precipitating factor is more controversial, although many case reports suggested this hypothesis [42, 43]. In prospective studies analyzing the effects of DAs on macroprolactinomas, PA were very rarely or never observed [6, 44, 45, 46]. In a retrospective study [9], DA treatment of pituitary adenomas was not associated with PA. These results are not surprising, given that these agents decrease growth and activity of prolactinoma or other adenoma cells.

PA can occur in the setting of an acute systemic illness such as myocardial infarction or severe infection. Excessive stimulation of the pituitary gland by production of larger amount of steroids is a possible explanation [33].

4.1.3. Anticoagulated states

PA has been observed after administration of anticoagulant drugs (vitamin K antagonist or platelet inhibitors) or thrombolytic agents, sometimes very soon after the initiation of treatment or after a prolonged period of treatment [6, 9, 47]. New classes of anticoagulant (dabigatran) [48, 49] may also be involved.

Thrombocytopenia has also been reported usually associated with hemorrhagic PA [50, 51].

4.2. Influence of pituitary adenoma type

The prevalence of apoplexy according to different subtypes of pituitary tumors shows a trend for nonfunctioning adenomas [3, 4, 5, 9, 22, 33, 52, 53, 54, 55] to develop apoplexy. It is believed that nonfunctioning tumors may be diagnosed at a later stage, so they grow to a larger size before diagnosis; in contrast, the functioning adenomas are generally revealed earlier by signs of hormonal secretion before bleeding/infarction occurs [5].

Other tumor types predisposing to apoplexy are prolactinomas and GH-secreting adenomas [27, 56, 57, 58, 59]. In the vast majority of cases, apoplexy complicates large macroadenomas [10]. Clinically silent ACTH adenomas may be particularly prone to necrosis, hemorrhage, and cyst transformation [5, 60]. These complications occur in 30–64% of cases, 2–14% in patients with all types of pituitary adenoma [16, 61, 62, 63].

Advertisement

5. Clinical presentation

Frequently, the PA episode is the first manifestation of undiagnosed pituitary adenoma [22, 57, 64].

It is important to consider that the pituitary apoplexy has a wide spectrum of clinical features, resulting from undergoing sudden mass enlargement. It ranges from silent asymptomatic necrotic and/or hemorrhagic adenoma to “classic” acute presentation and even death.

This is largely depending on the extent of hemorrhage, necrosis, and edema. Semple et al. suggested that the cases of pituitary tumor infarction alone had less severe clinical features and better outcome than those with hemorrhagic infarction or frank hemorrhage [15].

The clinical manifestations are summarized in Table 2.

Table 2.

Common clinical features of pituitary apoplexy.

5.1. Neurologic symptoms

Headache is the earliest and most common presenting symptom with an incidence of more than 90% [4, 65, 66].

The cephalalgia onset is often sudden and severe, namely, “thunderclap headache,” in patients presenting with pituitary apoplexy and creates an even greater degree of difficulty in the differential diagnoses. It is usually resistant to analgesics, mainly retro-orbital and sometimes bifrontal, suboccipital, or diffuse [67]. This feature can be explained by meningeal irritation due to extravasation of blood and necrotic material into subarachnoid space, enlargement of sella turcica walls, dura mater compression, or involvement of the superior division of the trigeminal nerve inside the cavernous sinus [18, 68].

Headache is commonly accompanied by signs of meningeal irritation, such as nausea and vomiting (57%), photophobia (40%), meningismus (25%), and fever (16%) [5]. The fifth cranial nerve (first branch) can be involved in PA, resulting in facial numbness [3].

Altered level of consciousness may occur in varying degrees ranging from lethargy to stupor or even coma as consequence of blood or necrotic tissue leaking into the subarachnoid space [69]. A concurrent cerebrovascular episode with a stroke has been previously described [70]. The involvement of the thalamus in a case of pituitary apoplexy with thalamic and midbrain infarction has been described [71]. In such cases, one of the following mechanisms was proposed: (1) compression of intracavernous portion of internal carotid artery due to expanding pituitary adenoma or a hemorrhage within it and (2) vasospasm caused by factors released from hemorrhagic or necrotic material [70].

Rare cases of sudden death following pituitary tumor apoplexy of fatal outcome of acute pituitary apoplexy due to massive hemorrhage were reported [72, 73].

5.2. Visual disturbance

The apoplectic pituitary adenoma can expand toward the cavernous sinus, compressing the III, IV, and/or IV cranial nerves (CN), leading to various degrees of ocular palsy (diplopia and ophthalmoplegia) in 40–70% of the patients [52, 55, 74, 75].

The third CN is the most frequently affected especially when there is an abutment without invasion of the cavernous sinuses. This was explained mainly by the location of the third nerve in the same horizontal plane as the pituitary gland; pressure from lateral growth of a pituitary tumor is relatively easily transmitted to the third cranial nerve. This leads to compression of the third cranial nerve between the tumor and the interclinoid ligament, commonly resulting in the development of the third cranial nerve palsy, occurring either alone or together with damage to the other cranial nerves [52, 76].

Isolated cranial nerve palsy III in PA with direct CN III compression outside the cavernous sinus was also reported. In these cases, the tumor had some mass effect on CN III at the level of the oculomotor trigone after erosion of the posterior clinoid [77]. Multiple CN palsies and even bilateral and asymmetric lesions have been reported [78, 79, 80]. Rarely, pituitary apoplexy may present as isolated sixth cranial nerve (abducens) palsy [81].

Compression of the necrotic intrasellar mass superiorly toward the optic nerves and optic chiasma causes visual symptoms in most (75%) patients [11, 76], including decreased visual acuity; visual field defects, especially bitemporal hemianopsia; and also complete blindness and monocular blindness.

Advertisement

6. Differential diagnosis

As stated earlier, PA occurs in previously unknown history of pituitary mass in more than 80% of patients, the diagnosis can be challenging owing to its similarities with many other neurological conditions, and several other life-threatening conditions (Table 3) can lead to a delay in proper management [11].

Table 3.

Differential diagnoses of pituitary apoplexy.

The two most important diseases that should be considered are aneurysmal subarachnoid hemorrhage (SAH) and bacterial meningitis, subarachnoid hemorrhage [82, 83], bacterial meningitis, or parasellar abscess [84, 85].

Other differential diagnoses include subarachnoid hemorrhage, ophthalmoplegic migraine, suprasellar aneurysm, stroke and hypertensive encephalopathy, and cavernous sinus thrombosis [52, 82, 83, 85, 86, 87].

Nevertheless, a high degree of suspicion should exist in any patient presenting a severe sudden headache and visual disturbances. This aims to avoid delay in proper management.

Imaging studies are thus crucial for the diagnosis.

Advertisement

7. Endocrine function

7.1. Pituitary hormone excess

As most cases of pituitary apoplexy complicate pituitary macroadenoma, many of which are secretory.

Prolactinomas are the most common (20% of cases of pituitary apoplexy); this is related to the frequency of prolactinoma in the population and to their frequent hemorrhagic nature. Hyperprolactin can also result from stalk effect [88].

It was postulated that at presentation of PA in non-PRL-secreting macroadenomas, a normal or elevated serum PRL can predict the residual anterior pituitary cell viability. Inversely a very low serum PRL level at presentation is correlated with the necrosis of the normal pituitary tissue and predicts permanent hypopituitarism [89].

More rarely PA can occur in acromegaly and Cushing’s disease (too much adrenocorticotropic hormone, ACTH) in approximately 7 and 3% of cases, respectively. Co-secretion of more than one hormone may occur.

Several published series reported clinical and biochemical resolution of hormonally hyperfunctioning pituitary adenomas (including Cushing’s disease and acromegaly) following pituitary apoplexy on follow-up as a result of the infarction of the pituitary tumors [90, 91, 92, 93].

7.2. Pituitary hormone deficiency

Reviewing the series of patients with PA, one or more endocrine deficiencies can be present at the onset [22, 67, 76] and the evaluation of hormonal levels is mandatory (Table 4).

Table 4.

Endocrine disorders in pituitary apoplexy.

The pathogenesis of hypopituitarism is complex and multifactorial.

As most episodes of PA occur in macroadenoma, the pituitary hormone deficiencies can precede the apoplectic event [22, 76].

This was explained earlier by mechanical compression of the pituitary stalk and/or the portal vessels. But more recent study suggested that it is tightly related to pressure effect of the macroadenoma, as they indicated that in patients with large pituitary adenomas, the intrasellar pressure, measured at surgery, was greater in patients who had hypopituitarism than those with intact pituitary function [94].

Moreover, the apoplexy itself can cause ischemic necrosis of the anterior pituitary secondary to a sudden rise in intrasellar pressure compressing the portal circulation, the pituitary stalk, and the pituitary gland itself [89, 95].

The most life-threatening deficit is that of adrenocorticotropic hormone (ACTH) resulting in acute central hypoadrenalism, which has been reported in more than 70% of patients [36, 52, 76]. It can result in severe hemodynamic problems. Indeed, the absence of cortisol can lead to insensitivity of the vessels to the pressor effects of endogenous or exogenous catecholamines and thus in hemodynamic instability.

Therefore, in patients with PA, empiric parental corticosteroid supplementation should be given immediately.

In the acute setting, other hormone deficiencies have less concerns. At presentation thyrotropic deficiency and gonadotropic deficiency were reported in 30–70% and 40–75% of patients, respectively [3].

Posterior pituitary involvement is not common in PA, and diabetes insipidus was reported in 3% of cases despite frequent and significant suprasellar extension in many cases [10, 96].

This may be attributable to the preservation of the posterior pituitary as a result of its different blood supply from the inferior hypophyseal artery rather than the superior hypophyseal artery that supplies the anterior pituitary and usually the tumor.

7.3. Fluid electrolyte balance: hyponatremia

Hyponatremia is a common electrolyte disturbance reported in up to 40% of patients presenting with pituitary apoplexy [22].

In most cases, hyponatremia is mostly mild, but severe hyponatremia has been reported [96, 97, 98, 99].

It is often multifactorial and the most likely pathogenetic mechanism proposed of hyponatremia is adrenal insufficiency.

Other etiologies can include the syndrome of inappropriate ADH secretion (SIADH) resulting either from adrenal insufficiency itself or from hypothalamus irritation [99] and neurological deterioration late after initial presentation.

Hypothyroidism as common hormone deficiency in pituitary apoplexy may contribute to hyponatremia by reduction in glomerular filtration rate and elevated ADH secretion [100].

An association of a high level of atrial natriuretic peptide concomitant to a high level of ADH, a severe scenario in hyponatremic patients after pituitary apoplexy, has been demonstrated [99].

7.4. Pituitary imaging

In emergency setting, most of the patients with symptoms related to PA will undergo computed tomography (CT) as it is readily available and a rapid screening test. It is likely that, in most of them, the clinical suspicion might be something other than PA.

CT is effective in visualizing pituitary heterogeneous intrasellar and/or expansive suprasellar lesions leading to sellar enlargement (up to 94% of cases) [5, 20, 25], with a coexistence of solid and hemorrhagic areas [4, 22, 76, 101].

The CT is also able to detect subarachnoid hemorrhage and cerebral ischemia, which are the most frequent complications of PA [101].

CT is most valuable in the acute phase (up to 48 h). The recent bleeding in this phase can be missed on MRI either because of infarction or because hemorrhage is still in the form of deoxyhemoglobin. In this context, CT is able to provide an improved detection of hyperdense intralesional areas [102].

Later, during the subacute or chronic phase, in line with blood degradation, hypodense intralesional areas can be present, which increases the difficulty to make the differential diagnosis of subacute hemorrhages from other necrotic or cystic lesions (aneurysms, meningiomas, Rathke cleft cysts, germinomas, and lymphoma) [101].

This makes MRI essential to differentiate between these conditions. MRI and MR angiogram techniques also help to distinguish an aneurysm from pituitary apoplexy [4, 22, 85, 103].

Nevertheless, magnetic resonance imaging (MRI) is the radiological investigation of choice. Its findings depend on the time of onset of bleeding.

It is possible to find a fluid in the intralesional level (Figure 1(C)), the lower area is constituted by red cell sediment, and the cranial corresponds to free extracellular methemoglobin.

Figure 1.

MRI in a pregnant patient, with symptomatic pituitary apoplexy. The lesion is globally hypointense, hemorrhagic content of the pituitary mass, and the hemorrhagic area, in T1-weighted sequences ((A) coronal section, (B) sagittal section), with a high signal intensity (arrow (B)) corresponding to the cystic area. In the same patient, the coronal T2-weighted sequences (C) showing a fluid level (asterisk) inside the pituitary lesion: the upper compartment being hyperintense while the lower is isointense.

In the acute stage of pituitary apoplexy, the MRI signal is isointense or slightly hypointense on T1-weighted imaging with hypointensity on T2-weighted imaging (T2 W1). A “brushed” specific pattern of alternating subtle T1-hyperintense and T1-hypointense areas within the sellar mass may suggest apoplexy at the earlier stage [101].

Later, there is marginal signal reinforcement and the hematoma core remains isointense; in the subacute phase, the hemorrhage will appear hyperintense on T1WI as well as on T2WI. In the chronic phase, macrophages digest the clot, and the presence of hemosiderin and ferritin causes a strong hypointensity on both T1WI and T2WI [101].

In pituitary apoplexy patients, some authors reported the thickening of the sphenoid sinus mucosa related to venous engorgement in this region as an excellent sign that is present from the early stage, a reversible condition on follow-up studies that generally improves spontaneously [104]. This thickening does not indicate infectious sinusitis and thus does not rule out the surgical transsphenoidal route [103, 105].

Some published series have demonstrated the great value of special techniques as T2-weighted gradient echo to detect pituitary hemorrhage in the acute phase and chronic phase. MRI diffusion-weighted images (DWI) can be also be helpful in rare cases of ischemic pituitary necrosis without hemorrhage [105, 106, 107].

Semple et al. have demonstrated a correlation with the MRI findings and histopathology in 68% of patients with a histopathological diagnosis of hemorrhagic infarction/hemorrhage and in 82% of patients with infarction alone [103].

Advertisement

8. Pituitary apoplexy management

PA has long been considered as a neurosurgical emergency. However, nowadays, the conservative approach constitutes another therapeutic option in many situations. Untreated patients with apoplexy have higher morbidity and mortality. Altered consciousness, with all its associated complications, hypopituitarism, and intercurrent illnesses account for the increased morbidity and mortality of untreated patients. Although it is hard to estimate the relative increase in mortality associated without treatment, reports published before corticosteroid therapy were available indicating an approximate mortality rate of 50% [3].

The goals of treatment of PA are to improve symptoms, to decompress local structures especially the optic tract, and to avoid acute adrenal insufficiency. Hence, whether the treatment is surgical or conservative, glucocorticosteroid replacement is systematic.

8.1. Glucocorticosteroid replacement and emergency medical treatment

As corticotropic deficiency is frequently associated with pituitary apoplexy, corticosteroid should be systematically given to these patients. Thus, hydrocortisone is administered at a dose of 50 mg every 6 h [3, 108] or in the form of a 100–200 mg bolus followed by 50–100 mg every 6 h intravenously (or intramuscularly) or by 2–4 mg per hour by continuous intravenous infusion [108, 109]. Corticosteroid substitution should be associated with a careful assessment of fluid and electrolyte balance and supportive measures ensuring hemodynamic stability. Once glucocorticoids are administered, clinical improvement is invariably observed, and hemodynamic stability becomes easier to maintain. The glucocorticoids are administered in supraphysiological doses to serve not only as replacement for endogenous hormone deficiency but also to help control the effect of edema on parasellar structures [3].

8.2. Neurosurgical treatment

8.2.1. Technique

If surgical management is chosen, the transsphenoidal approach is almost always recommended, because it allows good decompression of the optic pathways and neuroanatomic structures in contact with the tumor and because it is associated with low postoperative morbidity and mortality [11]. Usually, necroticohemorrhagic material is evacuated as soon as the incision of the tumor capsule is made. The purpose of the surgery is the decompression of the optical pathways; the surgeon should try to identify the sellar diaphragm. In case of invasive pituitary adenoma, a maximum but incomplete resection is ensured by taking all the precautions to avoid damaging the cranial nerves or the carotids in case of invasion of the cavernous sinuses.

8.2.2. Timing

The timing of pituitary surgery is controversial, as no randomized trials comparing different strategies with strong evidence have been performed. However, most studies indicate that surgical treatment, usually within 7 days after the apoplectic event, leads to higher rates of visual impairment recovery [11, 110].

Occasionally, patients are clinically or biochemically hypothyroid at presentation. Unless the hypothyroidism is severe, the surgical decompression needs not be delayed, provided the anesthesiologists and the management team are aware of the patient’s condition to avoid medications and procedures that are particularly deleterious and that can potentially worsen clinical symptoms [3].

8.2.3. Outcomes

Surgical decompression normalizes visual acuity in about one-half of cases and improves it in another 6–36% of cases [52, 53]. Visual field defects normalize after surgery in 30–60% of cases and improve in another 50%. Ocular motility dysfunction can resolve spontaneously, with or without surgery [111].

Pituitary deficiencies are usually not expected to recover [19, 112]. In addition, it seems that apoplexy worsens endocrine outcome: hormonal prognosis after elective pituitary surgery is poorer in patients with PA than in patients without PA [9]. This is explained mainly by the damage to the normal gland from the initial apoplectic event. Another important point is that, in this acute setting, the operation may be performed by an on-call neurosurgeon rather than by a skilled pituitary neurosurgeon, as underlined in UK guidelines [11], and this may increase the risk of adverse events.

For tumoral outcome, complete tumor removal is reported in 48–66% of patients and subtotal resection in 23–52% of patients [95]. Tumor recurrence has been described in 6–11% of patients [112].

8.2.4. Surgical complications

Surgery may also be harmful, with a risk of postoperative cerebrospinal fluid leakage, permanent diabetes insipidus caused by posterior pituitary damage, meningitis, and an increased likelihood of hypopituitarism due to removal or damage to normal pituitary tissue. Fortunately, in experienced pituitary centers, these complications are very rare [5].

8.3. Conservative approach: rationale, modalities, and outcomes

Several reports have documented that spontaneous neurological recovery is possible despite unilateral ophthalmoplegia and partial visual field defects, which has suggested that nonoperative medical management of patients with PA may be appropriate in many situations. In 1995, Maccagnan et al. reported the results of a prospective study in which they treated PA with high-dose steroids (2 to 16 mg of dexamethasone daily). Only patients whose visual impairment or altered consciousness failed to improve underwent surgery. Conservative treatment was possible on 7 of 12 patients, and only 5 patients had needed surgery. Visual deficits regress in 6 of the 7 patients and improved in the remaining patients. The posttreatment prevalence of pituitary hormone deficiency and the incidence of tumor regrowth were similar in conservatively and surgically treated patients [113].

Thus, conservative therapy involved supportive therapy, continued use of supraphysiological doses of glucocorticoids for several weeks, and hormone replacement therapy. Improvement in neurological symptoms is often seen in the majority of patients treated conservatively, at times to a similar degree to that seen in surgically treated patients. However, worsening of pituitary function is usually seen in many of these patients [114]. For functioning pituitary adenomas, hormonal secretion must be also evaluated: hormonal levels could be low, be normal, or remain high after apoplexy [11]. For tumoral outcomes, additional treatment is not necessary in most cases, as tumors usually diminish and even disappear without surgical intervention [10]. It seems that a single large hypodense area within the tumor on CT might be associated with better subsequent tumor shrinkage than are several small hypodense areas [113].

8.4. Surgical or conservative treatment?

PA is characterized by a highly capricious course, and randomized prospective studies with strong evidence about this syndrome are lacking, which makes optimal management of acute PA controversial. Although guidelines, as the one from the UK, proposed an algorithm for PA management, randomized trials comparing both strategies are needed for strong evidence [11, 112]. Hence, the decision of surgical treatment or conservative management should be individualized and made by experts from a multidisciplinary team including endocrinologists, neurologists, ophthalmologists, and neurosurgeon [11].

The risk-benefit ratio of conservative treatment versus surgery must be carefully evaluated, in terms of visual outcome, pituitary function and also subsequent tumor growth. On the other hand, the potentially serious complications of surgery need to be taken into consideration [115].

8.4.1. Background

In spite of the methodological limits of the studies available on this subject, these data have constituted the rationale guiding the therapeutic choice of PA.

The outcome of visual acuity, field defect, or ophthalmoplegia is similar with surgery or conservative treatment. Unfortunately, visual outcome is poorer in patients with more severe disorders such as monocular or binocular blindness, irrespective of whether management is conservative or surgical [56, 116, 117]. It has been argued that conservatively treated patients may have less severe visual defects than surgically treated patients and that this might explain why the improvement is at least as good in the former as in the latter [3, 11, 118]. The number of patients with visual defects was effectively higher in the surgical groups of published series [53, 76].

For endocrine prognosis, whatever the management approach, the hormonal outcome is poor in patients with PA, who frequently suffer irreversible pituitary damage [11].

Concerning the outcome of the pituitary tumor, very few studies have compared the degree of tumor disappearance between patients receiving surgery and conservative treatment for apoplexy. The reported results were very different: the incidence of recurrence was similar between the two approaches in one study [76], higher after surgery in one other [56], and lower after surgery in two others [52]. Thus, the optimal approach for tumor control is difficult to judge. Whatever the therapeutic choice in the acute event, additional forms of therapy can be used to control residual tumor growth, depending on the type of tumor, including a dopamine agonist for documented prolactinomas or a somatostatin analogue for documented growth hormone-secreting tumors. Gamma Knife stereotactic radiosurgery can also be used on these patients and on patients with nonsecreting adenomas [3].

8.4.2. MRI’s contribution to the therapeutic choice

MRI did not predict the severity of ocular paresis or field defects. The size of the tumor on MRI is not actually a strong argument for therapeutic choice. Even when the tumor was very large, conservative management was accompanied by tumor shrinkage [76]. However, some MRI findings were found to be associated with clinical status and outcome: patients with simple infarction had less severe clinical features and better outcomes than those with hemorrhagic infarction or hemorrhage [70].

All these data from the literature have allowed deducing overall the place of, respectively, the conservative approach and the surgical treatment in the management of PA.

8.4.3. Surgical treatment indications

According to the majority of authors, surgical intervention should be considered in patients with severely reduced visual acuity, severe and persistent visual field defects, and deteriorating level of consciousness despite glucocorticoid replacement and hydroelectrolytic support [109]. Ocular paresis because of involvement of III, IV, or VI cranial nerves in the cavernous sinus is not in itself an indication for immediate surgery. Resolution will typically occur within days or weeks with conservative management [11].

The UK Guidelines for PA recommend a scoring system (Table 5), calculated using visual acuity, visual defects, cranial nerve palsies, and the Glasgow Coma Scale. The PA score ranges from 0 to 10, and surgery usually is indicated for scores ≥4 [11]. Another scoring system, from the Massachusetts General Hospital, proposes grading patients on a scale from 1 to 5: grade 1 for asymptomatic individuals, grade 2 for patients with symptoms due to endocrinopathy, grade 3 for patients with headache, grade 4 for patients with ocular paresis, and grade 5 for patients with visual deficits or a low Glasgow Coma Scale score. Patients with grade 5 should be submitted to surgery [59].

Table 5.

Pituitary apoplexy score (PAS).

8.4.4. Conservative management indications

For conservative approach, it is safe in patients with pituitary tumor apoplexy who are without any neuro-ophthalmic signs or mild and stable signs or those with evidence of early improvement after administration of glucocorticoids [76]. This would be particularly applicable in patients with prolactin-secreting adenomas, with whom dopamine agonists are very effective not only in controlling hyperprolactinemia but also in reducing the size of the adenoma [3]. “Wait-and-see” approach should be also considered in patients with significant clinical comorbidities.

If conservative treatment is chosen, then careful monitoring of visual signs and symptoms is necessary, and surgical decompression is recommended if visual disorders do not improve or if they deteriorate [5, 11, 59].

8.5. Follow-up

All patients with pituitary apoplexy need follow-up by endocrine and neurosurgical teams. They require repeated assessment of pituitary and visual function (visual acuity, eye movements, and visual fields), at 4–6 weeks. Thereafter, hormonal reevaluation must be performed every 6–12 months to determine whether or not the pituitary defect is permanent and the possible hypersecretory nature of the adenoma and to optimize hormonal replacement [109].

Sellar MRI should be repeated in 3–6 months, annually for 5 years, and biannually after that to monitor tumor progression/recurrence [119]. The presence of an “empty sella” is often observed [117].

Morbidity and mortality in patients with pituitary tumor apoplexy have declined in the past six decades. Four factors may have contributed to the improved survival: improved diagnostic accuracy, use of glucocorticoids, use of more sophisticated supportive therapy, and refinements in surgical techniques and postoperative care [3]. Currently, mortality in the acute setting is less than 2% [120].

Advertisement

9. Conclusion

PA is uncommon but a potentially life-threatening complication due to acute infarction or hemorrhage within a preexisting pituitary adenoma. Its pathophysiology, including extrinsic compression of arterial supply or intrinsic tumoral factors, is still controversial. In terms of triggering factors, the most common include major surgery. The classical presentation is highly suspected when an acute lancinating headache is combined with visual disturbance, cranial nerve palsy, and hypopituitarism. MRI is a fundamental step to evaluate the pituitary infarct and hemorrhage and to rule out other pathologies. For the management of PA, corticosteroids should be systematically administered. However, the therapeutic choice between surgery and conservative treatment is controversial and should be made by experts from a multidisciplinary team. The surgical management which used to be considered as the first-line treatment of this acute condition is now reserved for patients with severe neuro-ophthalmic signs. Improvement of the diagnostic means and the therapeutic management has allowed a better PA prognosis which is preserved in most of the cases. Reevaluation of the pituitary function and tumor mass is mandatory in the months after the acute apoplectic episode to adjust hormonal substitution, to detect the possible hypersecretory nature of the adenoma, and to initiate follow-up of a possible tumor remnant.

References

  1. 1. Bailey P. Pathological report of a case of acromegaly, with special reference to the lesion in the hypophysis cerebri and in the thyroid gland; and a case of haemorrhage into the pituitary. The Philadelphia medical Journal. 1898;1:789-792
  2. 2. Brougham M, Heusner AP, Adams RD. Acute degenerative changes in adenomas of the pituitary body-with special reference to pituitary apoplexy. Journal of Neurosurgery. 1950;7:421-439
  3. 3. Nawar RN, Abdel Mannan D, Selman WR, Arafah BM. Pituitary tumor apoplexy: A review. Journal of Intensive Care Medicine. 2008;23:75-90. DOI: 10.1177/0885066607312992
  4. 4. Dubuisson AS, Beckers A, Stevenaert A. Classical pituitary tumour apoplexy: Clinical features, management and outcomes in a series of 24 patients. Clinical Neurology and Neurosurgery. 2007;109:63-70. DOI: 10.1016/j.clineuro.2006.01.006
  5. 5. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology. 2010;72:377-382. DOI: 10.1111/j.1365-2265.2009.03667.x
  6. 6. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in northern Finland in 1992-2007. The Journal of Clinical Endocrinology and Metabolism. 2010;95:4268-4275. DOI: 10.1210/jc.2010-0537
  7. 7. Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary apoplexy. Endocrine Reviews. 2015;36:622-645. DOI: 10.1210/er.2015-1042
  8. 8. Nielsen EH, Lindholm J, Bjerre P, et al. Frequent occurrence of pituitary apoplexy in patients with nonfunctioning pituitary adenoma. Clinical Endocrinology. 2006;64:319-322. DOI: 10.1111/j.1365-2265.2006.02463.x
  9. 9. Wildemberg LE, Glezer A, Bronstein MD, Gadelha MR. Apoplexy in nonfunctioning pituitary adenomas. Pituitary. 2018;21:138-144. DOI: 10.1007/s11102-018-0870-x
  10. 10. Möller-Goede DL, Brändle M, Landau K, Bernays RL, Schmid C. Pituitary apoplexy: Re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. European Journal of Endocrinology. 2011;164:37-43. DOI: 10.1530/EJE-10-0651
  11. 11. Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clinical Endocrinology (Oxford). 2011;74:9-20. DOI: 10.1111/j.1365-2265.2010.03913.x
  12. 12. Vargas G, Gonzalez B, Ramirez C, Ferreira A, Espinosa E, Mendoza V, Guinto G, Lopez-Felix B, Zepeda E, Mercado M. Clinical characteristics and treatment outcome of 485 patients with nonfunctioning pituitary macroadenomas. International Journal of Endocrinology. 2015:756069. DOI: 10.1155/2015/756069
  13. 13. Jankoswski PP, Crawford JR, Khanna P, Malicki DM, Ciacci JD, Levy ML. Pituitary tumor apoplexy in adolescents. World Neurosurgery. 2015;83:644-645. DOI: 10.1016/j.wneu.2014.12.026
  14. 14. Glezer A, Bronstein MD. Pituitary apoplexy: Pathophysiology, diagnosis and management. The Archives of Endocrinology and Metabolism. 2015;59:259-264. DOI: 10.1590/2359-3997000000047
  15. 15. Semple PL, De Villiers JC, Bowen RM, Lopes MB, Laws ER. Pituitary apoplexy: Do histological features influence the clinical presentation and outcome? Journal of Neurosurgery. 2006;104:931-937. DOI: 10.3171/jns.2006.104.6.931
  16. 16. Sarwar KN, Huda MS, Van de Velde V, Hopkins L, Luck S, Preston R, et al. The prevalence and natural history of pituitary hemorrhage in prolactinoma. The Journal of Clinical Endocrinology and Metabolism. 2013;98(6):2362-2367. DOI: 10.1210/jc.2013-1249
  17. 17. Oldfield EH, Merrill MJ. Apoplexy of pituitary adenomas: The perfect storm. Journal of Neurosurgery. 2015;122:1444-1449. DOI: 10.3171/2014.10.JNS141720
  18. 18. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas and the normal pituitary gland. The Journal of Clinical Endocrinology and Metabolism. 2000;85:1159-1162. DOI: 10.1210/jcem.85.3.6485
  19. 19. Bills DC, Meyer FB, Laws ER Jr, et al. A retrospective analysis of pituitary apoplexy. Neurosurgery. 1993;33:602-609
  20. 20. Kruse A, Astrup J, Cold GE, Hansen HH. Pressure and blood flow in pituitary adenomas measured during transsphenoidal surgery. British Journal of Neurosurgery. 1992;6:333-341
  21. 21. Xekouki P, Mastroyiannis SA, Avgeropoulos D, et al. Familial pituitary apoplexy as the only presentation of a novel AIP mutation. Endocrine-Related Cancer. 2013;20:5. DOI: 10.1530/ERC-13-0218
  22. 22. Louwerens M, de Herder WW, Postema PT, Tanghe HL, Lamberts SW. Pituitary insufficiency and regression of acromegaly caused by pituitary apoplexy following cerebral angiography. European Journal of Endocrinology. 1996;134:737-740. DOI: 10.1530/eje.0.1340737
  23. 23. Skljarevski V, Khoshyomn S, Fries TJ. Pituitary apoplexy in the setting of coronary angiography. Journal of Neuroimaging. 2003;13:276-279. DOI: 10.1177/1051228403254656
  24. 24. Weisberg LA. Pituitary apoplexy. Association of degenerative change in pituitary adenoma with radiotherapy and detection by cerebral computed tomography. The American Journal of Medicine. 1977;63:109-115. DOI: 10.1016/0002-9343(77)90122-X
  25. 25. Bhatt G, Bhatt AD, Silverman CL, Dragun AE. Pituitary apoplexy after hypo-fractionated stereotactic radiotherapy. Journal of Solid Tumors; 26 Mar 2013;3(3):22
  26. 26. Smidt MH, van der Vliet A, Wesseling P, de Vries J, Twickler TB, Vos PE. Pituitary apoplexy after mild head injury misinterpreted as bacterial meningitis. European Journal of Neurology. 2007;14:e7-e8. DOI: 10.1111/j.1468-1331.2007.01644.x
  27. 27. Mayrin JV, Laufgraben M. Pituitary apoplexy following cardiac surgery: A case report and review of the literature. Endocrinologist. 2007;7(4):214-216. DOI: 10.1097/TEN.0b013e3180ca7786
  28. 28. Liberale G, Bruninx G, Vanderkelen B, Dubois E, Vandueren E, Verhelst G. Pituitary apoplexy after aortic abdominal aneurysm surgery: A case report. Acta Chirurgica Belgica. 2006;106:77-80. DOI: 10.1080/00015458.2006.11679839
  29. 29. Mizuno T. Pituitary apoplexy with third cranial nerve palsy after off-pump coronary artery bypasses grafting. Interactive CardioVascular and Thoracic Surgery. 2011;13:240-242. DOI: 10.1510/icvts.2011.268854
  30. 30. Levy E, Korach A, Merin G, Feinsod M, Glenville B. Pituitary apoplexy and CABG: Should we change our strategy? The Annals of Thoracic Surgery. 2007;84:1388-1390. DOI: 10.1016/j.athoracsur.2007.05.017
  31. 31. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: Clinical features, management and outcome. Clinical Endocrinology. 1999;51:181-188. DOI: 10.1046/j.1365-2265.1999.00754.x
  32. 32. Mou C, Han T, Zhao H, Wang S, Qu Y. Clinical features and immunohistochemical changes of pituitary apoplexy. Journal of Clinical Neuroscience. 2009;16:64-68. DOI: 10.1016/j.jocn.2008.02.012
  33. 33. Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. Neurology, Neurosurgery & Psychiatry. 2001;71:542-545. DOI: 10.1136/jnnp.71.4.542
  34. 34. Rotman-Pikielny P, Patronas N, Papanicolaou DA. Pituitary apoplexy induced by corticotrophin releasing hormone in a patient with Cushing’s disease. Clinical Endocrinology. 2003;58:545-549. DOI: 10.1046/j.1365-2265.2003.01720.x
  35. 35. Yamamoto T, Yano S, Kuroda J-i, Yu H, Hide T, Kuratsu J-i. Pituitary apoplexy associated with endocrine stimulation test: Endocrine stimulation test, treatment, and outcome. Research article. Case Reports in Endocrinology. 2012.https://doi.org/10.1155/2012/826901
  36. 36. Semple PL, Jane JA Jr, Laws ER Jr. Clinical relevance of precipitating factors in pituitary apoplexy. Neurosurgery. 2007;61:956-961. discussion 961-962. DOI: 10.1227/01.neu.0000303191.57178.2a
  37. 37. Heide LJ, van Tol KM, Doorenbos B. Pituitary apoplexy presenting during pregnancy. The Netherlands Journal of Medicine. 2004;62:393-396.http://www.njmonline.nl/getpdf.php?id=259
  38. 38. Parihar V, Yadav YR, Sharma D. Pituitary apoplexy in a pregnant woman. Annals of Indian Academy of Neurology. 2009;12:54-55. DOI: 10.4103/0972-2327.48861
  39. 39. Keane F, Egan AM, Navin P, Brett F, Dennedy MC. Gonadotropin-releasing hormone agonist-induced pituitary apoplexy. Endocrinology, Diabetes & Metabolism Case Reports. 2016;2016:160021. DOI: 10.1530/EDM-16-0021
  40. 40. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer. International Journal of Urology. 2006;13:303-304. DOI: 10.1111/j.1442-2042.2006.01237.x
  41. 41. Huang TY, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS. Pituitary apoplexy induced by gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case. World Journal of Surgical Oncology. 2013;11:254.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851712/
  42. 42. Knoepfelmacher M, Gomes MC, Melo ME, Mendonça BB. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary. 2004;7:83-87. DOI: 10.1186/1477-7819-11-254
  43. 43. Balarini Lima GA, Machado Ede O, Dos Santos Silva CM, Filho PN, Gadelha MR. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary. 2008;11:287-292. DOI: 10.1007/s11102-007-0046-6
  44. 44. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2247-2252. DOI: 10.1210/jcem.85.6.6657
  45. 45. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A. Prolactinomas resistant to standard doses of cabergoline: A multicenter study of 92 patients. European Journal of Endocrinology. 2012;167:651-662. DOI: 10.1530/EJE-12-0236
  46. 46. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients. European Journal of Endocrinology. 2009;160:747-752. DOI: 10.1530/EJE-09-0012
  47. 47. Nagarajan DV, Bird D, Papouchado M. Pituitary apoplexy following anticoagulation for acute coronary syndrome. Heart. 2003;89:10. DOI: 10.1136/heart.89.1.10
  48. 48. Uemura MMF, Shimomura R, Fujinami J, Toyoda K. Pituitary apoplexy during treatment with dabigatran. Neurology and Clinical Neuroscience. 2013;1:82-83. DOI: 10.1002/ncn3.18
  49. 49. Doglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A. New oral anticoagulants and pituitary apoplexy. Pituitary. 2016;19(2):232-234. DOI: 10.1007/s11102-014-0616-3
  50. 50. Maïza JC, Bennet A, Thorn-Kany M, Lagarrigue J, Caron P. Pituitary apoplexy and idiopathic thrombocytopenic purpura: A new case and review of the literature. Pituitary. 2004;7:189-192. DOI: 10.1007/s11102-005-1760-6
  51. 51. Wongpraparut N, Pleanboonlers N, Suwattee P, Rerkpattanapipat P, Turtz A, Moster M, Gala I, Kim YN. Pituitary apoplexy in a patient with acute myeloid leukemia and thrombocytopenia. Pituitary. 2000;3:113-116. DOI: 10.1023/A:1009909908942
  52. 52. Sibal L, Ball SG, Connolly V, James RA, Kane P, Kelly WF, Kendall-Taylor P, Mathias D, Perros P, Quinton R, Vaidya B. Pituitary apoplexy: A review of clinical presentation, management and outcome in 45 cases. Pituitary. 2004;7:157-163. DOI: 10.1007/s11102-005-1050-3
  53. 53. Leyer C, Castinetti F, Morange I, Gueydan M, Oliver C, Conte-Devolx B, Dufour H, Brue T. A conservative management is preferable in milder forms of pituitary tumor apoplexy. Journal of Endocrinological Investigation. 2011;34:502-509. DOI: 10.3275/7241
  54. 54. Vargas G, Gonzalez B, Guinto G, Mendoza V, López-Félix B, Zepeda E, Mercado M. Pituitary apoplexy in nonfunctioning pituitary macroadenomas: A case-control study. Endocrine Practice. 2014;20:1274-1280. DOI: 10.4158/EP14120.OR
  55. 55. Pal A, Capatina C, Tenreiro AP, Guardiola PD, Byrne JV, Cudlip S, Karavitaki N, Wass JA. Pituitary apoplexy in non-functioning pituitary adenomas: Long term follow up is important because of significant numbers of tumour recurrences. Clinical Endocrinology. 2011;75:501-504. DOI: 10.1111/j.1365-2265.2011.04068.x
  56. 56. Gruber A, Clayton J, Kumar S, Robertson I, Howlett TA, Mansell P. Pituitary apoplexy: Retrospective review of 30 patients–is surgical intervention always necessary? British Journal of Neurosurgery. 2006;20:379-385. DOI: 10.1080/02688690601046678
  57. 57. Semple PL, Webb MK, de Villiers JC, Laws ER Jr. Pituitary apoplexy. Neurosurgery. 2005;56:65-73. discussion 62-73. DOI: 10.1227/01.NEU.0000144840.55247.38
  58. 58. Khaldi M, Ben Hamouda K, Jemel H, Kallel J, Zemmel I. Pituitary apoplexy. Report of 25 patients. Neuro-Chirurgie. 2006;52:330-338. DOI: NCHIR-09-2006-52-4-0028-3770-101019-200604684
  59. 59. Jho DH, Biller BM, Agarwalla PK, Swearingen B. Pituitary apoplexy: Large surgical series with grading system. World Neurosurgery. 2014;82:781-790. DOI: 10.1016/j.wneu.2014.06.005
  60. 60. Chan D, Rong TC, Dalan R. Cushing’s disease presenting with pituitary apoplexy. Journal of Clinical Neuroscience. 2012;19:1586-1589. DOI: 10.1016/j.jocn.2011.10.017
  61. 61. Kinoshita Y, Tominaga A, Usui S, Arita K, Sugiyama K, Kurisu K. Impact of subclinical haemorrhage on the pituitary gland in patients with pituitary adenomas. Clinical Endocrinology. 2014;80:720-725. DOI: 10.1111/cen.12349
  62. 62. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws ER Jr, Young WF Jr. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47:723-729. discussion 729-730. DOI: 10.1097/00006123-200009000-00039
  63. 63. Sahli R, Christ ER, Seiler R, Kappeler A, Vajtai I. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: Report of four cases and literature review. Pathology, Research and Practice. 2006;202:457-464. DOI: 10.1016/j.prp.2006.01.007
  64. 64. Lubina A, Olchovsky D, Berezin M, Ram Z, Hadani M, Shimon I. Management of pituitary apoplexy: Clinical experience with 40 patients. Acta Neurochirurgica. 2005;147:151-157. DOI: 10.1007/s00701-004-0413-2
  65. 65. Russel SJ, Miller KK. Pituitary apoplexy. In: Swearingen B, Biller BMK, editors. Diagnosis and Management of Pituitary Disorders. Totowa, NJ: Humana Press; 2008. pp. 353-375
  66. 66. Shimon I. Clinical features of pituitary apoplexy. In: Turgut M, Mahapatra AK, Powell M, Muthukumar N, editors. Pituitary Apoplexy. Berlin, Heidelberg: Springer-Verlag; 2014. pp. 49-54
  67. 67. Johnston PC, Hamrahian AH, Weil RJ, Kennedy L. Pituitary tumor apoplexy. Journal of Clinical Neuroscience. 2015;22(6):939-944. DOI: 10.1016/j.jocn.2014.11.023
  68. 68. Satyarthee GD, Mahapatra AK. Pituitary apoplexy in a child presenting with massive subarachnoid and intraventricular hemorrhage. Journal of Clinical Neuroscience. 2005;12:94-96. DOI: 10.1016/j.jocn.2003.10.030
  69. 69. Sugand K, Metcalfe D, Jaiganesh T. Subarachnoid haemorrhage with pituitary adenoma. In: Turgut M, Mahapatra AK, Powell M, Muthukumar N, editors. Pituitary Apoplexy. Berlin, Heidelberg, Germany: Springer-Verlag; 2014. pp. 55-67
  70. 70. Ahmed SK, Semple PL. Cerebral ischaemia in pituitary apoplexy. Acta Neurochirurgica. 2008;150:1193-1196. discussion 1196. DOI: 10.1007/s00701-008-0130-3
  71. 71. Verma R, Singh S, Patil TB. Thalamic infarction in pituitary apoplexy syndrome. BML Case Reports. 2012 Oct;12:2012. DOI: 10.1136/bcr-2012-006993
  72. 72. Bauer M, Lang C, Patzelt D. Sudden death due to pituitary apoplexy. Legal Medicine (Tokyo). 2001;3(3):183-186. DOI: 10.1016/S1344-6223(01)00026-8
  73. 73. Shields LB, Balko MG, Hunsaker JC 3rd. Sudden and unexpected death from pituitary tumor apoplexy. Journal of Forensic Sciences. 2012;57:262-266. DOI: 10.1111/j.1556-4029.2011.01906.x
  74. 74. Hage R, Eshraghi SR, Oyesiku NM, Ioachimescu AG, Newman NJ, Biousse V, Bruce BB. Third, fourth, and sixth cranial nerve palsies in pituitary apoplexy. World Neurosurgery. 2016;94:447-452. DOI: 10.1016/j.wneu.2016.07.026
  75. 75. Zhu X, Wang Y, Zhao X, Jiang C, Zhang Q, Jiang W, Chen H, Shou X, Zhao Y, Li Y, Li S, Ye H. Incidence of pituitary apoplexy and its risk factors in chinese people: A database study of patients with pituitary adenoma. PLoS One. 2015;10:e0139088. DOI: 10.1371/journal.pone.0139088
  76. 76. Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJ. Acute management of pituitary apoplexy–surgery or conservative management? Clinical Endocrinology. 2004;61:747-752. DOI: 10.1111/j.1365-2265.2004.02162.x
  77. 77. Kobayashi H, Kawabori M, Terasaka S, Murata J, Houkin K. A possible mechanism of isolated oculomotor nerve palsy by apoplexy of pituitary adenoma without cavernous sinus invasion: A report of two cases. Acta Neurochirurgica. 2011;153(12):2453-2456. DOI: 10.1007/s00701-011-1165-4
  78. 78. Delgado-Alvarado M, Riancho J, Riancho-Zarrabeitia L, Sedano MJ, Polo JM, Berciano J. Unilateral total ophthalmoplegia without visual loss as the presenting form of a pituitary apoplexy. Revista Clínica Española. 2013;213:e67-e70. DOI: 10.1016/j.rce.2013.05.009
  79. 79. Diyora B, Nayak N, Kukreja S, Kamble H. Sudden onset isolated complete third nerve palsy due to pituitary apoplexy. Oman Journal of Ophthalmology. 2011;4:32-34. DOI: 10.4103/0974-620X.77661
  80. 80. Tanriverdi F, Karaca Z, Oner A, Durak AC, Selcuklu A, Unluhizarci K, Kelestimur F. Complete surgical resolution of bilateral total opthalmoplegia without visual field defect in an acromegalic patient presented with pituitary apoplexy. Endocrine Journal. 2007;54:681-684. DOI: 10.1507/endocrj.K07-008
  81. 81. Zoli M, Mazzatenta D, Pasquini E, Ambrosetto P, Frank G. Cavernous sinus apoplexy presenting isolated sixth cranial nerve palsy: Case report. Pituitary. 2012;15(Suppl 1):37-40. DOI: 10.1007/s11102-011-0312-5
  82. 82. Tedd HM, Tuckett J, Arun C, Dhar A. An unusual case of sudden onset headache due to pituitary apoplexy: A case report and review of the new UK guidelines. The Journal of the Royal College of Physicians of Edinburgh. 2012;42:119-123. DOI: 10.4997/JRCPE.2012.206
  83. 83. Ni CD, Lambert J. Sudden headache, third nerve palsy and visual deficit: Thinking outside the subarachnoid haemorrhage box. Age and Ageing. 2013;42:810-812. DOI: 10.1093/ageing/aft088
  84. 84. Wong SH, Das K, Javadpour M. Pituitary apoplexy initially mistaken for bacterial meningitis. BMJ Case Reports. 5 Sept 2013;2013:bcr2013009223
  85. 85. Paisley AN, Syed AA. Pituitary apoplexy masquerading as bacterial meningitis. Canadian Medical Association Journal. 2012;184:1812. DOI: 10.1503/cmaj.120174
  86. 86. Silvestrini M, Matteis M, Cupini LM, Troisi E, Bernardi G, Floris R. Ophthalmoplegic migraine-like syndrome due to pituitary apoplexy. Headache. 1994;34:484-486. DOI: 10.1111/j.1526-4610.1994. hed3408484.x
  87. 87. Verrees M, Arafah BM, Selman WR. Pituitary tumor apoplexy: Characteristics, treatment, and outcomes. Neurosurgical Focus. 2004;16:E6. DOI: 10.3171/foc.2004.16.4.7
  88. 88. Skinner DC. Rethinking the stalk effect: A new hypothesis explaining suprasellar tumor-induced hyperprolactinemia. Medical Hypotheses. 2009;72(3):309-310. DOI: 10.1016/j.mehy.2008.08.030
  89. 89. Zayour DH, Selman WR, Arafah BM. Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: Relation to pituitary function. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5649-5654. DOI: 10.1210/jc.2004-0884
  90. 90. Marko NF, Hamrahian AH, Hatipoglu B, et al. Relapsing remitting hypercortisolism in Cushing’s disease due to intratumoral hemorrhages in pituitary microadenoma. Journal of Clinical Neuroscience. 2013;20:753-756. DOI: 10.1016/j.jocn.2012.05.039
  91. 91. Cinar N, Metin Y, Dagdelen S, et al. Spontaneous remission of acromegaly after infarctive apoplexy with a possible relation to MRI and diabetes mellitus. Neuro Endocrinology Letters. 2013;34:339-342. DOI: 10.1210/endo-meetings. 2010.PART3.P6.P3-283
  92. 92. Fraser LA, Lee D, Cooper P, et al. Remission of acromegaly after pituitary apoplexy: Case report and review of literature. Endocrine Practice. 2009;15:725-731. DOI: 10.4158/EP09126.CR
  93. 93. Choudhry OJ, Choudhry AJ, Nunez EA, et al. Pituitary tumor apoplexy in patients with Cushing’s disease: Endocrinologic and visual outcomes after transsphenoidal surgery. Pituitary. 2012;15:428-435. DOI: 10.1007/s11102-011-0342-z
  94. 94. Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 2000;85:1789-1793. DOI: 10.1210/jc.85.5.1789
  95. 95. Capatina C, Inder W, Karavitaki N, Wass JA. Management of endocrine disease: Pituitary tumour apoplexy. European Journal of Endocrinology. 2015;172:R179-R190. DOI: 10.1530/EJE-14-0794
  96. 96. Sweeney AT, Blake MA, Adelman LS, et al. Pituitary apoplexy precipitating diabetes insipidus. Endocrine Practice. 2004;10:135-138. DOI: 10.4158/EP.10.2.135
  97. 97. Ebner FH, Hauser TK, Honegger J. SIADH following pituitary adenoma apoplexy. Neurological Sciences. 2010;31:217-218. DOI: 10.1007/s10072-009-0210-z
  98. 98. Krull I, Christ E, Kamm CP, Ganter C, Sahli R. Hyponatremia associated coma due to pituitary apoplexy in early pregnancy: A case report. Gynecological Endocrinology. 2010;26:197-200. DOI: 10.3109/09513590903184118
  99. 99. Agrawal D, Mahapatra AK. Pituitary apoplexy and inappropriate ADH secretion. Journal of Clinical Neuroscience. 2003;10(2):260-261. DOI: 10.1016/S0967-5868(03)00002-X
  100. 100. Iglesias P, Diez JJ. Thyroid dysfunction and kidney disease. European Journal of Endocrinology. 2009;160:503-515. DOI: 10.1530/EJE-08-0837
  101. 101. Bonneville JF, Bonneville F. Pituitary apoplexy. In: Catin F, Nagi S, editors. MRI of the Pituitary Gland. Vol. 2014. Switzerland: Springer; 2016. pp. 89-95. DOI: 10.1007/978-3-319-29043-0_13
  102. 102. Freeman WD. Pituitary apoplexy. Neurocritical Care. 2005;3:174-176. DOI: 10.1385/NCC:3:2:174
  103. 103. Semple PL, Jane JA, Lopes MBS, Laws ER. Pituitary apoplexy: Correlation between magnetic resonance imaging and histopathological results. Journal of Neurosurgery. 2008;108:909-915. DOI: 10.3171/JNS/2008/108/5/0909
  104. 104. Agrawal B, Dziurzynski K, Shariar Salamat M, Baskaya M. The temporal association of sphenoid sinus mucosal thickening on MR imaging with pituitary apoplexy. Turkish Neurosurgery. 2012;22(6):785-790. DOI: 10.5137/1019-5149.JTN.4273-11.1
  105. 105. Waqar M, McCreary R, Kearney T, Karabatsou K, Gnanalingham KK. Sphenoid sinus mucosal thickening in the acute phase of pituitary apoplexy. Pituitary. 2017;20(4):441-449. DOI: 10.1007/s11102-017-0804-z
  106. 106. Rogg JM, Tung GA, Anderson G, Cortez S. Pituitary apoplexy: Early detection with diffusion-weighted MR imaging. AJNR. American Journal of Neuroradiology. 2002;23:1240-1245.http://www.ajnr.org/content/ajnr/23/7/1240
  107. 107. Bonneville F, Cattin F, Marsot-Dupuch K, Dormont D, Bonneville JF, Chiras J. T1 signal hyperintensity in the sellar region: Spectrum of findings. Radiographics. 2006;26:93-113. DOI: 10.1148/rg.261055045
  108. 108. Chanson P, Briet C, Salenave S. Médecine clinique endocrinologie et diabète. L’apoplexie hypophysaire. 2015;78.https://www.mced.fr/archives/mced/78/lapoplexiehypophysaire.html
  109. 109. Baldeweg SE, Vanderpump M, Drake W, et al. Emergency management of pituitary apoplexy in adult patients. Endocrine Connections. 2016;5(5):12-15. DOI: 10.1530/EC-16-0057
  110. 110. Abdulbaki A, Kanaan I. The impact of surgical timing on visual outcome in pituitary apoplexy: Literature review and case illustration. Surgical Neurology International. 2017;8:16. DOI: 10.4103/2152-7806.199557
  111. 111. Tu M, Lu Q, Zhu P, Zheng W. Surgical versus non-surgical treatment for pituitary apoplexy: A systematic review and meta-analysis. Journal of the Neurological Sciences. 2016;370:258-262. DOI: 10.1016/j.jns.2016.09.047
  112. 112. Briet C, Salenave S, Chanson P. Pituitary apoplexy. Endocrinology and Metabolism Clinics of North America. 2015;44:199-209. DOI: 10.1210/er.2015-1042
  113. 113. Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J. Conservative management of pituitary apoplexy: A prospective study. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2190-2197. DOI: 10.1210/jcem.80.7.7608278
  114. 114. Pelkonen R, Kuusisto A, Salmi J, et al. Pituitary function after pituitary apoplexy. The American Journal of Medicine. 1978;65:773-778. DOI: 10.1016/0002-9343(78)90795-7
  115. 115. Chanson P, Salenave S. Conservative management of pituitary apoplexy. In: Turgut M, Mahapatra AK, Powell M, Muthukumar N, editors. Pituitary Apoplexy. Berlin, Heidelberg, Germany: Springer-Verlag; 2014. pp. 151-156
  116. 116. Turgut M, Ozsunar Y, Basak S, Guney E, Kir E, Meteoglu I. Pituitary apoplexy: An overview of 186 cases published during the last century. Acta Neurochirurgica. 2010;152:749-761. DOI: 10.1007/s00701-009-0595
  117. 117. Muthukumar N, Rossette D, Soundaram M, Senthilbabu S, Badrinarayanan T. Blindness following pituitary apoplexy: Timing of surgery and neuro-ophthalmic outcome. Journal of Clinical Neuroscience. 2008;15:873-879. DOI: 10.1016/j.jocn.2007.08.010
  118. 118. Bujawansa S, Thondam SK, Steele C, et al. Presentation, management and outcomes in acute pituitary apoplexy: A large single-centre experience from the United Kingdom. Clinical Endocrinology. 2014;80:419-424. DOI: 10.1111/cen.12307
  119. 119. Boellis A, di Napoli A, Romano A, Bozzao A. Pituitary apoplexy: An update on clinical and imaging features. Insights Imaging. 2014;5:753-762. DOI: 10.1007/s13244-014-0362-0
  120. 120. Bi WL, Dunn IF, Laws ER. Pituitary apoplexy. Endocrine. 2015;48:69-75. DOI: 10.1007/s12020-014-0359

Written By

Manel Jemel, Wafa Alaya, Fedia Boubaker, Olfa Berrich and Baha Zantour

Submitted: February 6th, 2018 Reviewed: April 16th, 2018 Published: November 5th, 2018